# QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer

> **NCT07286240** · PHASE2 · RECRUITING · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Treatment of Recurrent Ovarian Cancer

## Interventions

- **DRUG:** QL1706 plus chemotherapy and anlotinib regimen

## Key facts

- **NCT ID:** NCT07286240
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-15
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286240, "QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07286240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*